Please login to the form below

Not currently logged in

UK launch for gastrointestinal pharma firm

Belgian gastrointestinal pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate

Belgian gastrointestinal (GI) pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate.

Movetis (UK) will focus on the production of novel drugs to be used in the treatment of GI-related diseases where current options are limited.

The UK team includes eight representatives experienced in GI disorders. They will work with a range of products including Resolor (prucalopride), a treatment for chronic constipation in women in whom laxatives fail to provide adequate relief. Resolor was launched in the UK in March, 2010.

The company has said it plans further research involving prucalopride beyond its current indication.

Two products are currently in phase II development for Movetis, with a further two prioritised compounds in preclinical development. All products are aimed at addressing unmet needs in GI treatment.

David Trevor, general manager of Movetis (UK) said "The expansion of the business into the UK is an exciting time for Movetis. As a specialist GI pharmaceutical company we are able to focus our efforts and concentrate on ensuring new treatment options are made available for the management of gastrointestinal disease."

28th July 2010


Featured jobs

Subscribe to our email news alerts


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...